KLRS - Kalaris Therapeutics, Inc. Year-over-year net earnings per share growth for the last 12 months

Kalaris Therapeutics, Inc. (KLRS) - corporate logo

Kalaris Therapeutics Inc (KLRS) relies on patent-protected molecules to ensure a stable cash flow. The development of retinal therapies is supported by unique drug delivery methods. Strong physician interest in clinical trials confirms the brand's scientific authority. Quarterly earnings per share (EPS) growth illustrates financial stability, where the value 26.70 represents the current figure for this metric.

Kalaris Therapeutics (KLRS) Year-over-year net earnings per share change for the last twelve months: for the period 03/20/2025 - 11/18/2026

KLRS (kalaristx.com): analytical breakdowns and indicator data

- market value and analyst target forecast:
- market capitalization statistics:
Fundamental valuation:Kalaris Therapeutics Inc. - KLRS
Flagship merchandise of Kalaris Therapeutics Inc

Developing viral therapies in collaboration with medical centers requires significant expenditures, so the quarterly earnings per share trend for Kalaris Therapeutics Inc (KLRS) allows for an assessment of capital management efficiency and the impact of fiscal factors on net value. The current value of 26.70 reflects profit growth rates, helping investors correlate the risks of frozen funds with the asset's potential yield during the intervals between financial reports.

Competitor analysis

Gilead Sciences Inc (GILD) - Year-over-year earnings per share growth for the last twelve months|Cidara - Year-over-year earnings per one share growth for the last 12 months|Year-over-year net earnings per share growth for the last 12 months NVAX|Quarterly EPS earnings growth curevac.com|Year-over-year earnings per share growth for the last twelve months Valneva Corp (VALN)|Year-over-year earnings per share growth for the last twelve months VIR (Vir Biotechnology)|Year-over-year earnings per share growth for the last twelve months TPOXX SIGA|EBS - Year-over-year net earnings per share growth for the last 12 months|AVIR: Year-over-year net earnings per share growth for the last 12 months|IVVD (Invivyd Inc) - Year-over-year earnings per share growth for the last 12 months|ENTA: Quarterly EPS earnings growth|INO (Inovio) - Year-over-year earnings per share growth for the last twelve months|Year-over-year earnings per share growth for the last twelve months HilleVax Corp|Year-over-year earnings per share growth for the last 12 months DYAI (Dyadic International)|Year-over-year net earnings per share growth for the last 12 months NNVC (NanoViricides)|TLPH (Talphera, Inc.) - Year-over-year earnings per one share growth for the last 12 months|Year-over-year earnings per share growth for the last twelve months Cocrystal Pharma Inc COCP|Year-over-year earnings per one share growth for the last 12 months TRAW|Dogwood Therapeutics Inc. - Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months Qualigen Corp|ALVR (AlloVir Bio) - Year-over-year net earnings per share growth for the last 12 months|Year-over-year net earnings per share growth for the last 12 months VBI Vaccines, Inc.|VIRI (virios.com) - Quarterly EPS earnings growth|Year-over-year earnings per share growth for the last 12 months VXRT (Vaxart, Inc.)